Toxicity patterns associated with chemotherapy/immune checkpoint inhibitor combinations: a meta-analysis

Atezolizumab for First-Line Treatment of Metastatic Nonsquamous NSCLC

(2018) Mark A. Socinski et al.   NEW ENGLAND JOURNAL OF MEDICINE

Pembrolizumab plus Chemotherapy in Metastatic Non–Small-Cell Lung Cancer

(2018) Leena Gandhi et al.   NEW ENGLAND JOURNAL OF MEDICINE

Pembrolizumab plus Chemotherapy for Squamous Non–Small-Cell Lung Cancer

(2018) Luis Paz-Ares et al.   NEW ENGLAND JOURNAL OF MEDICINE

Immune-related ocular toxicities in solid tumor patients treated with immune checkpoint inhibitors: a systematic review

(2017) Omar Abdel-Rahman et al.   Expert Review of Anticancer Therapy

Immune-related neurological toxicities among solid tumor patients treated with immune checkpoint inhibitors: a systematic review

(2017) Mostafa Eltobgy et al.   Expert Review of Neurotherapeutics

Immune-related musculoskeletal toxicities among cancer patients treated with immune checkpoint inhibitors: a systematic review

(2017) Omar Abdel-Rahman et al.   Immunotherapy

Phase III Trial of Ipilimumab Combined With Paclitaxel and Carboplatin in Advanced Squamous Non–Small-Cell Lung Cancer

(2017) Ramaswamy Govindan et al.   JOURNAL OF CLINICAL ONCOLOGY

Immune-related neurological toxicities among solid tumor patients treated with immune checkpoint inhibitors: a systematic review

(2017) Mostafa Eltobgy et al.   Expert Review of Neurotherapeutics

Treatment-associated Fatigue in Cancer Patients Treated with Immune Checkpoint Inhibitors; a Systematic Review and Meta-analysis

(2016) O. Abdel-Rahman et al.   CLINICAL ONCOLOGY

Phase III Randomized Trial of Ipilimumab Plus Etoposide and Platinum Versus Placebo Plus Etoposide and Platinum in Extensive-Stage Small-Cell Lung Cancer

(2016) Martin Reck et al.   JOURNAL OF CLINICAL ONCOLOGY

Carboplatin and pemetrexed with or without pembrolizumab for advanced, non-squamous non-small-cell lung cancer: a randomised, phase 2 cohort of the open-label KEYNOTE-021 study

(2016) Corey J Langer et al.   LANCET ONCOLOGY

Risk of pneumonitis in cancer patients treated with immune checkpoint inhibitors: a meta-analysis

(2016) Omar Abdel-Rahman et al.   Therapeutic Advances in Respiratory Disease

Combining immunotherapy and anticancer agents: the right path to achieve cancer cure?

(2015) L. Apetoh et al.   ANNALS OF ONCOLOGY

Risk of elevated transaminases in cancer patients treated with immune checkpoint inhibitors: a meta-analysis

(2015) Omar Abdel-Rahman et al.   Expert Opinion On Drug Safety

Nivolumab versus Everolimus in Advanced Renal-Cell Carcinoma

(2015) Robert J. Motzer et al.   NEW ENGLAND JOURNAL OF MEDICINE

The Interplay of Immunotherapy and Chemotherapy: Harnessing Potential Synergies

(2015) Leisha A. Emens et al.   Cancer Immunology Research

Preferred Reporting Items for Systematic Reviews and Meta-Analyses: The PRISMA Statement

(2013) David Moher   ANNALS OF INTERNAL MEDICINE

Ipilimumab in combination with paclitaxel and carboplatin as first-line therapy in extensive-disease-small-cell lung cancer: results from a randomized, double-blind, multicenter phase 2 trial†

(2012) M. Reck et al.   ANNALS OF ONCOLOGY

Ipilimumab in Combination With Paclitaxel and Carboplatin As First-Line Treatment in Stage IIIB/IV Non–Small-Cell Lung Cancer: Results From a Randomized, Double-Blind, Multicenter Phase II Study

(2012) Thomas J. Lynch et al.   JOURNAL OF CLINICAL ONCOLOGY

Ipilimumab plus Dacarbazine for Previously Untreated Metastatic Melanoma

(2011) Caroline Robert et al.   NEW ENGLAND JOURNAL OF MEDICINE